Preclinical study reveals tumor-localized immune activation by bispecific ATOR-4066 in human CD40 transgenic mice, highlighting potential for targeted cancer immunotherapy.
Key Points
ATOR-4066 drives localized immune cell activation and tumor destruction by cross-linking CD40 on antigen presenting cells with CEACAM5 in the tumor microenvironment.
Flow cytometry reveals increased tumor-infiltrating immune cells and selective upregulation of CD86 on dendritic cells, demonstrating restricted microenvironmental activity.
Preclinical evaluation in human CD40 transgenic mice demonstrates strong anti-tumor responses; mouse model, further translational validation and clinical testing are warranted.